Home » Newsletters » BioWorld Science

BioWorld Science

July 21, 2004

View Archived Issues

Nudix hydrolases show promise as antibiotic targets in tuberculosis

Cel-Sci reviews recent progress

Bavarian Nordic and GlaxoSmithKline in global Imvamune collaboration

First phase III study of GVAX prostate cancer vaccine commences enrollment

Phase II results for INKP-102

Completion of financing round at Acuity

Therapeutic benefits of mitoxantrone in multiple sclerosis

Acamprosate does not affect alcohol pharmacokinetics and pharmacodynamics

Telomerase inhibitor inhibits glioblastoma growth in vivo

LY-411575 tested in novel animal model of Alzheimer's

Novel therapeutic polyagent for Alzheimer's disease therapy

Aeolus name change completed

FDA extends review period for low-dose Yasmin NDA

European approval for Teveten Plus

AOP Orphan obtains Thromboreductin registrations in Central Europe

First phase II monotherapy study of 17-AAG begins

Novavax to reacquire rights to Estrasorb from King

Diversa signs agreement with GSK to advance novel antiinfective

Lower resistance to NNRTIs found with nevirapine plus Combivir in HIV-infected mothers

Low incidence of resistance to PIs found in HIV-infected patients treated with lopinavir/ritonavir

Novel cell penetrating peptides inhibit HIV-1 replication

Promising vitamin D analogue for the treatment of psoriasis

Antiinflammatory effects of PDE4 inhibitors on airways epithelial cell functions

Novel PARP inhibitors for the treatment of cerebral infarction

Sankyo isolates new antibacterial agents

Yamanouchi reports VEGF inhibitors for angiogenesis-related disorders

HIV integrase inhibitors described by Japan Tobacco

ProSkelia claims vitronectin receptor antagonists

Fujisawa discloses selective cyclooxygenase-1 inhibitors

Transdermal lidocaine for the treatment of neuropathic sensory loss

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.